Retinoblastoma Treatment Market Report 2026

The retinoblastoma treatment market size has grown strongly in recent years. It will grow from $2.15 billion in 2025 to $2.28 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to improvements in pediatric cancer diagnosis, expansion of specialized oncology centers, increased survival rates through early intervention, availability of advanced imaging tools, growing awareness of childhood eye cancers.

The retinoblastoma treatment market size is expected to see steady growth in the next few years. It will grow to $2.75 billion in 2030 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to increasing investments in pediatric oncology research, rising demand for minimally invasive therapies, expansion of precision medicine in oncology, growing focus on long-term quality of life outcomes, increasing adoption of advanced treatment delivery systems. Major trends in the forecast period include increasing adoption of targeted chemotherapy techniques, rising use of intra-arterial drug delivery, growing focus on vision-sparing treatments, expansion of multidisciplinary pediatric oncology care, enhanced early diagnosis and screening efforts.

The growing demand for ophthalmic treatments and surgical procedures is anticipated to drive the expansion of the retinoblastoma treatment market in the coming years. Ophthalmic treatments and surgeries include medical interventions and procedures used to diagnose, manage, and correct disorders affecting the eyes and visual system. The demand for these treatments is increasing due to factors such as aging populations, a higher incidence of eye conditions like cataracts and age-related macular degeneration, technological advancements that enable more effective and accessible therapies, and increased awareness that supports earlier detection and intervention. Retinoblastoma treatment plays a critical role within ophthalmic care by addressing malignant tumors within the eye, preventing metastasis or recurrence, and preserving vision and ocular function. For example, in October 2023, according to the Royal National Institute of Blind People (RNIB), a UK-based sight loss charity, eye care outpatient appointments in the UK exceeded eight million in 2022, the highest among all medical specialties, and the number of people living with sight loss, currently more than two million, is projected to double to over four million by 2050. Therefore, the rising demand for ophthalmic treatments and surgeries is fueling the growth of the retinoblastoma treatment market.

Major companies operating in the retinoblastoma treatment market are concentrating on the development of advanced therapeutic approaches, such as oncolytic virotherapy, to enhance treatment effectiveness while preserving vision in pediatric patients. Oncolytic virotherapy uses genetically engineered viruses that selectively infect and destroy cancer cells while sparing healthy tissue, thereby improving safety and reducing treatment-related side effects. For instance, in July 2024, Theriva Biologics, a US-based clinical-stage biotechnology company, received Rare Pediatric Disease Designation from the US Food and Drug Administration (FDA) for its lead candidate VCN-01, a systemically administered, stroma-degrading oncolytic adenovirus. VCN-01 selectively replicates in tumor cells, degrades tumor-associated stroma to enhance chemotherapy delivery, and stimulates immune activation against cancer cells. In a Phase 1 investigator-sponsored clinical trial involving pediatric patients with refractory retinoblastoma, intravitreal administration of VCN-01 demonstrated a favorable safety profile and promising clinical outcomes.

In May 2025, the International Society of Ocular Oncology (ISOO), a Switzerland-based organization dedicated to research, education, and global advocacy in ocular oncology, entered into a strategic partnership with the International Society of Paediatric Oncology (SIOP). Through this collaboration, both organizations aim to advance coordinated global efforts in retinoblastoma care by expanding access to high-quality treatments, improving clinical outcomes through shared expertise, and harmonizing care protocols across diverse healthcare systems. The International Society of Paediatric Oncology (SIOP) is a Switzerland-based multidisciplinary organization focused on improving outcomes for children with cancer.

Major companies operating in the retinoblastoma treatment market are Johnson And Johnson Services Inc., F Hoffmann La Roche AG, Merck And Co Inc., Sanofi SA, Bristol Myers Squibb Company, Novartis AG, Pfizer Inc., GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Otsuka Pharmaceutical, Daiichi Sankyo Company, Taiho Pharmaceutical Co Ltd, Icon Bioscience Inc., Ono Pharmaceutical Co Ltd, Nippon Shinyaku Co Ltd, Cadila Pharmaceuticals, Phio Pharmaceuticals Inc., Bayer AG, AstraZeneca Plc, Sun Pharmaceutical Industries Ltd.

North America was the largest region in the retinoblastoma treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinoblastoma treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the retinoblastoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the retinoblastoma treatment market by increasing the cost of imported chemotherapy drugs, advanced imaging systems, laser therapy equipment, and interventional delivery devices. Pediatric oncology centers in North America and Europe are most affected due to reliance on imported high-cost medical technologies, while emerging regions face affordability and access challenges. These tariffs are increasing treatment costs and influencing procurement strategies. However, they are also promoting local pharmaceutical manufacturing, regional oncology infrastructure development, and increased collaboration for cost-effective pediatric cancer care solutions.

The retinoblastoma treatment market research report is one of a series of new reports that provides retinoblastoma treatment market statistics, including retinoblastoma treatment industry global market size, regional shares, competitors with a retinoblastoma treatment market share, detailed retinoblastoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the retinoblastoma treatment industry. This retinoblastoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Retinoblastoma treatment refers to the medical interventions and therapies used to diagnose, manage, and potentially cure retinoblastoma. Retinoblastoma is a rare eye cancer that primarily affects young children, usually before the age of five. The main objective of treatment is to eliminate or control cancerous tumors within one or both eyes while preserving vision and reducing the risk of metastasis or recurrence.

The main types of retinoblastoma treatment include non-hereditary retinoblastoma and hereditary retinoblastoma. Non-hereditary retinoblastoma is an uncommon cancer that generally affects children under six years of age. It involves multiple treatment options such as surgery, radiation therapy, laser therapy (photocoagulation), cryotherapy, thermotherapy, chemotherapy, ophthalmic artery infusion chemotherapy, and high-dose chemotherapy with stem cell transplantation. These treatments are used for both intraocular and extraocular retinoblastoma stages and are commonly administered in hospitals, cancer institutes, and other healthcare settings.

The retinoblastoma treatment market consists of revenues earned by entities by providing services such as multidisciplinary care, genetic testing and counseling, remote patient monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The retinoblastoma treatment market also includes sales of targeted therapy medications, genetic testing kits and intravitreal chemotherapy injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.